A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma (original) (raw)

References

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Eng J Med352: 987–996, 2005
   Article CAS Google Scholar
2. Scott JN, Rewcastle NB, Hagen NA, Brasher PMA, Fulton D, MacKinnon JA, Hamiltong M, Cairncross JG, Forsyth P, Which glioblastoma multiforme patient will become a long-term survivor? A population based studyAnn Neurol46:183–188, 1999
   Article PubMed CAS Google Scholar
3. Dropcho EJ, 2001. Novel chemotherapeutic approaches to brain tumorsHematol Oncol Clin North Am 15:1027–1052
   Article PubMed CAS Google Scholar
4. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK, Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsJ Clin Oncol17:2572–2578, 1999
   PubMed CAS Google Scholar
5. Go RS, Adjei AA, Review of the comparative pharmacology and clinical activity of cisplatin and carboplatinJ Clin Oncol17:409–422, 1999
   PubMed CAS Google Scholar
6. Riccardi R, Riccardi A, Di Rocco C, Carelli G, Tartaglia RL, Lasorella A, Servidei T, Mastrangelo R, Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumorsCancer Chemother Pharmacol30:21–24, 1992
   Article PubMed CAS Google Scholar
7. Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM, Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primatesClin Cancer Res11:1669–1674, 2005
   Article PubMed CAS Google Scholar
8. Wolff JEA, Trilling T, Molenkamp G, Egleler RM, Jurgens H, Chemosensitivity of glioma cells in vitro: a meta analysisJ Cancer Res Clin Oncol125:481–486, 1999
   Article PubMed CAS Google Scholar
9. Poisson M, Pereon Y, Chiras J, Delattre JY, Treatment of recurrent malignant supratentorial gliomas with carboplatin J Neurooncol10:139–144, 1992
   Article Google Scholar
10. Yung WKA, Mechtler L, Gleason MJ, Intravenous carboplatin for recurrent malignant glioma: a phase II study J Clin Oncol9:860–864, 1991
    PubMed CAS Google Scholar
11. Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, Malec MK, A phase II study of intravenous carboplatin for the treatment of recurrent gliomasJ Neurooncol19:69–74, 1994
    Article PubMed CAS Google Scholar
12. Robertson JF, 2004. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspectiveCancer Treat Rev30(8):695–706
    Article PubMed CAS Google Scholar
13. Couldwell WT, Uhm J, Antel JP, Yong VW, Enhanced protein kinase C activity correlates with the growth rate of malignant human gliomasNeurosurgery29:880–887, 1991
    Article PubMed CAS Google Scholar
14. Couldwell WT, Antel JP, Apuzzo MLJ, Yong VW, Inhibition of growth of established human glioma lines by modulators of the protein kinase C second messenger systemJ Neurosurg73:594–600, 1990
    Article PubMed CAS Google Scholar
15. Couldwell WT, Antel JP, Yong VW, Protein kinase C activity and glioma growth (letter)J Neurosurg74:686–687, 1991
    Google Scholar
16. Couldwell WT, Antel JP, Yong VW, Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of PKCNeurosurgery31:717–724, 1992
    Article PubMed CAS Google Scholar
17. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosik FT, Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitroCancer Res50:7134–7138, 1990
    PubMed CAS Google Scholar
18. O’Brian CA, Liskamp RM, Solomon DH, Weinstein IB, Inhibition of protein kinase C by tamoxifenCancer Res45:2462–2465, 1985
    PubMed CAS Google Scholar
19. O’Brian CA, Liskamp RM, Solomon DH, Weinstein IB, Triphenylethylenes: a new class of protein kinase C inhibitorsJ Natl Cancer Inst76:1243–1246, 1986
    PubMed CAS Google Scholar
20. Zhang W, Yamada H, Sakai N, Niikawa S, Nozawa Y, Enhancement of radiosensitivity by tamoxifen in C6 glioma cellsNeurosurgery31:725–730, 1992
    Article PubMed CAS Google Scholar
21. Vertosick FT, Selker RG, Pollack IF, Arena V, The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of “failed” patientsNeurosurgery30:897–903, 1992
    Article PubMed Google Scholar
22. Chamberlain MC, Kormanik PA, Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomasArch Neurol56:703–708, 1999
    Article PubMed CAS Google Scholar
23. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio C, Weiner LP, Apuzzo ML, Masri L, Law RE, Weiss MH, Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifenClin Cancer Res2:619–622, 1996
    PubMed CAS Google Scholar
24. McClay EF, Albright KB, Jones JA, Eastman A, Christen R, Howell SB, Modulation of cisplatin resistance in human malignant melanoma cellsCancer Res52:6790–6796, 1992
    PubMed CAS Google Scholar
25. McClay EF, Albright KB, Jones JA, Christen RD, Howell SB, Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cellsCancer Res53:1571–1576, 1993
    PubMed CAS Google Scholar
26. Pollack IF, Kawecki BS, Lazo JS, Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitorJ Neurosurg84(6):1024–1032, 1996
    Article PubMed CAS Google Scholar
27. Mastronardi L, Farah JO, Puzzilli F, Ruggeri A, Tamoxifen modulation of carboplatin cytotoxicity in human U-138 glioma cell lineClin Neurol Neurosurg100:89–93, 1998
    Article PubMed CAS Google Scholar
28. Basu A, Lazo JS, Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1Cancer Res52:3119–3124, 1992
    PubMed CAS Google Scholar
29. Endicott JA, Ling V, The biochemistry of P-gIycoprotein-mediated multidrug resistanceAnnu Rev Biochem58:137–174, 1989
    Article PubMed CAS Google Scholar
30. Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P, Tamoxifen and carboplatin combination treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patientsJ Neurooncl38(1):59–68, 1998
    Article CAS Google Scholar
31. Puchner MJA, Herrmann H, Berger J, Cristante L, Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patientsJ Neurooncol49:147–55, 2000
    Article PubMed CAS Google Scholar
32. Macdonald DR, Cascino TL, Schold SC, Cairncross JG, Response criteria for phase II studies of malignant gliomaJ Clin Oncol8:1277–1280, 1990
    PubMed CAS Google Scholar
33. Fleming T, One-sample multiple testing procedure for phase II clinical trialsBiometrics38:143–151 1982
    Article PubMed CAS Google Scholar
34. Yung WKA, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA, Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First RelapseJ Clin Oncol17: 2762–2771, 1999
    PubMed CAS Google Scholar
35. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA, A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapseBr J Cancer83:588–593, 2000
    Article PubMed CAS Google Scholar
36. Fulton D, Urtasun R, Forsyth P, Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant gliomaJ Neurooncol27(2):149–155, 1996
    Article PubMed CAS Google Scholar
37. Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amista P, Nicolardi I, Sotti G. Ermani M, Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)J Clin Oncol22(23): 4779–4786, 2004
    Article PubMed CAS Google Scholar
38. Kappelle AC, Postma TJ, Taphorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC, Heimans JJ, PCV chemotherapy for recurrent glioblastoma multiformeNeurology56:118–120, 2001
    PubMed CAS Google Scholar

Download references